On October 11, 2023 Be Biopharma, Inc. ("Be Bio"), a company pioneering the discovery and development of Engineered B Cell Medicines (BeCMs), reported that Chief Executive Officer Joanne Smith-Farrell, Ph.D., will present at the annual Cell & Gene Meeting on the Mesa to be held October 10-12 in Carlsbad, California, and livestreamed globally (Press release, Be Biopharma, OCT 11, 2023, View Source [SID1234635847]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Details regarding the Be Biopharma presentation at the conference are as follows:
Event: 2023 Cell & Gene Meeting on the Mesa
Presentation: About B Cells: A New Class of Cellular Medicines
Date: October 11, 2023
Time:4:15-6:00pm PT
Location: Park Hyatt Aviara Resort, 7100 Aviara Resort Dr., Carlsbad, California 92011
Dr. Smith-Farrell will also participate on October 12 in an interactive discussion about resourcing strategies to support advancing innovation while meeting the practical and economic considerations of R&D.
Organized by the Alliance for Regenerative Medicine, the Cell & Gene Meeting on the Mesa is a three-day conference featuring more than 120 dedicated company presentations by leading public and private companies, highlighting technical and clinical achievements over the past 12 months in the areas of cell therapy, gene therapy, gene editing, tissue engineering, and broader regenerative medicine technologies, as well as over 100 panelists and featured speakers.
Virtual attendance is available, which includes a livestream of the Be Biopharma presentation and the ability to view all conference sessions on-demand. Please visit View Source for full information including registration. Complimentary attendance at this event is available for credentialed investors and members of the media only. Investors should contact Savannah Bryant at sbryant@alliancerm.org and interested media should contact Stephen Majors at smajors@alliancerm.org.
About B Cells – A New Class of Cellular Medicines
Imagine what could "Be?" In nature, a single B cell engrafts in the bone marrow and can produce thousands of proteins per second at constant levels over decades. B cells are nature’s exquisite medicine factories, manufacturing proteins to fight disease and maintain health. Unleashing the power of B cells is driving a new class of cellular medicines – Engineered B Cell Medicines (BeCMs). BeCMs have the potential to be durable, allogeneic, redosable and administered without toxic conditioning. The promise of BeCMs could transform therapeutic biologics with broad application — across protein classes, patient populations and therapeutic areas.